Re: The effect of low-dose naltrexone on quality of life of patients with MS: a randomized placebo-controlled trial.

The silence is deafening...............

On Jun 22, 7:05 pm, Tick <olt...@xxxxxxx> wrote:
Subject: The effect of low-dose naltrexone on quality of life of
patients with multiple sclerosis: a randomized placebo-controlled
trial.

Mult Scler. 2010 Jun 9. [Epub ahead of print]

The effect of low-dose naltrexone on quality of life of patients with
multiple
sclerosis: a randomized placebo-controlled trial.

Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N,
Shalbafan B.

Neurology Department, Jondi-Shapoor University of Medical Sciences,
Ahwaz, Iran.

Background: Low-dose naltrexone (LDN) may promote psychological well-
being as
well as generalized health especially in autoimmune disorders.

The objective of this study is to assess the effect of LDN on the
Quality of Life (QoL) of
patients with relapsing-remitting and secondary progressive multiple
sclerosis
(MS) using the scales and composite scores of the MSQoL-54
questionnaire.

Methods: A 17-week randomized, double-blind, placebo-controlled,
parallel-group,
crossover-design clinical trial was conducted in two universities. A
total of 96
adult patients aged between 15 and 65 years with relapsing-remitting
(RR) or
secondary progressive (SP) clinically definite MS with disease
duration longer
than 6 months enrolled into the study.

The primary outcome of the study was comparison of the scores of
physical and mental health by conducting independent t-test of the
results obtained in the middle and at the end of study between the two
groups.

Results: Variables including presence of pain, energy, emotional
well-being, social, cognitive, and sexual functions, role limitation
due to
physical and emotional problems, health distress, and overall QoL did
not show
any meaningful statistically difference between the two groups. Factor
analysis
revealed that health perception scores were statistically different
between the
groups before starting, in the middle, and at the end of the study.

Conclusion:
The study clearly illustrates that LDN is a relatively safe
therapeutic option in
RRMS and SPMS but its efficacy is under question and probably a long
duration
trial is needed in the future.

PMID: 20534644 [PubMed - as supplied by publisher]

===========================================
Searching the archives is available at:

http://community.lsoft.com/archives/AUTO-IMMUNE.html

.

Relevant Pages